| Format | Therapeutic Area | Target(s) | Immunization |
|
Preclinical | IND | Phase I | Status |
| BsAb | Oncology | PD-1 x CD40 |
|
Partnered | ||||
| BsAb | Oncology | OX40 x CTLA4 |
|
|||||
| BsAb | Oncology | 4-1BB x CD40 |
|
|||||
| BpAb | Inflammation and Autoimmunity | OX40 x OX40 |
|
Exclusive MTA evalsuation ongoing | ||||
| BsAb | Oncology | PD-L1 x 4-1BB |
|
|||||
| BsAb | Oncology | CTLA4 x TNFR2 |
|
|||||
| BsAb | Oncology | TIGIT x IL21 |
|
|||||
| BsAb | Oncology | OX40 x 4-1BB |
|
|||||
| BsAb | Oncology | CD70 x EGFR |
|
|||||
| BsAb | Oncology | PD-1 x VEGFA |
|
|||||
| BsAb | Oncology | GDF15 x VEGFA |
|
|||||
| BsAb | Inflammation and Autoimmunity | FCGRT x C2 |
|
|||||
| BsAb | Metabolism | IGHE x ASGR1 |
|
|||||
| Tri-Ab | Oncology | DLL3 x CD3E x 4-1BB |
|
|||||
| Tri-Ab | Oncology | PD-L1 x GDF15 x VEGFA |
|
|||||
| Tri-Ab | Oncology | PD-L1 x VEGFA x ALB |
|
|||||
| Tri-Ab | Oncology | CDH17 x CD3E x 4-1BB |
|
|||||
| Tri-Ab | Oncology | CD3 x DLL3 x ALB |
|
|||||
| Tri-Ab | Oncology | EGFR x PD-L1 x VEGFA |
|
|||||
| Tri-Ab | Oncology | PD-L1 x EGFR x MET |
|
|||||
| Tri-Ab | Oncology | GDF15 x VEGFA x PD-1 |
|
|||||
| Tri-Ab | Oncology, Autoimmunity | PD-1 x LAG-3 x TNF |
|
|||||
此外，，，，安安物联还拥有用于组装与CD3结合的双特异性抗体的类TCR抗体（TCR mimic）资产。。。。联系我们，，探索评估/许可/共同开发机会！！
